相关实验视频
Updated: Sep 13, 2025

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
史蒂维oside通过IRS1/PI3K/AKT信号通路改善了糖尿病前小鼠的肝脏胰岛素抵抗
Changfa Zhang1, Lili Kang2, Kangjun Li3
1Center For Clinical Epidemiology and Methodology (CCEM), The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
Molecular nutrition & food research
|July 25, 2025
概括
石酸是一种天然甜味剂,可改善糖尿病前期小鼠的葡萄糖耐受性和肝功能. 它通过调节IRS1/PI3K/AKT通路来改善肝脏的胰岛素抵抗,可能防止2型糖尿病 (T2DM) 的进展.
科学领域:
- 代谢健康 代谢健康
- 自然产品研究自然产品研究
- 分子内分泌学分子内分泌学
背景情况:
- 糖尿病前期发展为2型糖尿病 (T2DM) 是一个重大的健康问题.
- 针对肝脏胰岛素抵抗的饮食干预措施对于预防至关重要.
- 石酸是一种天然的甜味剂,具有抗糖尿病性质,但其对糖尿病前期肝脏胰岛素抵抗的影响尚不清楚.
研究的目的:
- 为了研究石化对糖尿病前期肝脏胰岛素耐药性的影响.
- 阐明stevioside对肝脏胰岛素抵抗的作用背后的分子机制.
主要方法:
- 通过高脂肪饮食诱导的糖尿病前小鼠被用石化治疗.
- 用RNA测序和基因丰富分析来研究肝脏基因表达.
- 棕酸诱导的胰岛素耐药AML-12细胞被用石酸治疗,并测量葡萄糖的摄取量.
- 定量逆转录PCR (qRT-PCR) 和西部抹杀评估了胰岛素信号通路的组成部分.
主要成果:
- 石酸改善了糖尿病前小鼠的葡萄糖耐受性和血胰岛素水平.
- 石酸增强了肝功能,改善了肝脏对胰岛素的抵抗.
- 分子分析显示,在小鼠和细胞模型中,石化调节了IRS1/PI3K/AKT信号通路.
结论:
- 史蒂维oside通过IRS1/PI3K/AKT通路有效改善糖尿病前期肝脏的胰岛素抵抗.
- 这些发现表明,化是预防T2DM进展的潜在饮食策略.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304

